Literature DB >> 1466079

Risk of infiltrating breast cancer subsequent to lobular carcinoma in situ. The Coordinating Center and Writing Committee of FONCAM (National Task Force for Breast Cancer).

S Ciatto1, L Cataliotti, G Cardona, S Bianchi.   

Abstract

The authors report on a retrospective consecutive multicentric series of 60 cases with histologic evidence of lobular carcinoma in situ (LCIS), followed for an average of 5.3 years. In the course of the follow-up, ipsilateral LCIS or infiltrating carcinoma occurred in 3 or 5 cases, respectively. Two LCIS reoccurrences and all ipsilateral infiltrating carcinomas were observed in 37 patients treated by limited surgery. Contralateral synchronous or metachronous carcinoma was observed in 3 or 2 cases, respectively (intraductal = 3, infiltrating = 2). Three patients died of breast cancer (2 with ipsilateral, 1 with ipsilateral and contralateral infiltrating carcinoma). The study confirms the higher risk of ipsilateral and contralateral cancer in LCIS patients and warns about the possible hazards of limited surgery in these cases.

Entities:  

Mesh:

Year:  1992        PMID: 1466079     DOI: 10.1177/030089169207800405

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  3 in total

1.  Loss of heterozygosity in lobular carcinoma in situ of the breast.

Authors:  S R Lakhani; N Collins; J P Sloane; M R Stratton
Journal:  Clin Mol Pathol       Date:  1995-04

2.  Interpretation of the risk associated with the unexpected finding of lobular carcinoma in situ.

Authors:  S Zurrida; C Bartoli; V Galimberti; R Raselli; L Barletta
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

3.  Most lobular carcinoma in situ and atypical lobular hyperplasia diagnosed on core needle biopsy can be managed clinically with radiologic follow-up in a multidisciplinary setting.

Authors:  Lavinia P Middleton; Nour Sneige; Robin Coyne; Yu Shen; Wenli Dong; Peter Dempsey; Therese B Bevers
Journal:  Cancer Med       Date:  2014-03-18       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.